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Background: Despite being a critical survivorship care issue, there is a clear gap in current knowledge of the
optimal treatment of sexual dysfunction in men with prostate cancer. There is sound theoretical rationale and
emerging evidence that exercise may be an innovative therapy to counteract sexual dysfunction in men with
prostate cancer. Furthermore, despite the multidimensional aetiology of sexual dysfunction, there is a paucity of
research investigating the efficacy of integrated treatment models. Therefore, the purpose of this study is to:
1) examine the efficacy of exercise as a therapy to aid in the management of sexual dysfunction in men with
prostate cancer; 2) determine if combining exercise and brief psychosexual intervention results in more
pronounced improvements in sexual health; and 3) assess if any benefit of exercise and psychosexual intervention
on sexual dysfunction is sustained long term.
Methods/Design: A three-arm, multi-site randomised controlled trial involving 240 prostate cancer survivors will be
implemented. Participants will be randomised to: 1) ‘Exercise’ intervention; 2) ‘Exercise + Psychosexual’ intervention;
or 3) ‘Usual Care’. The Exercise group will receive a 6-month, group based, supervised resistance and aerobic
exercise intervention. The Exercise + Psychosexual group will receive the same exercise intervention plus a brief
psychosexual self-management intervention that addresses psychological and sexual well-being. The Usual Care
group will maintain standard care for 6 months. Measurements for primary and secondary endpoints will take place
at baseline, 6 months (post-intervention) and 1 year follow-up. The primary endpoint is sexual health and secondary
endpoints include key factors associated with sexual health in men with prostate cancer.
Discussion: Sexual dysfunction is one of the most prevalent and distressing consequences of prostate cancer.
Despite this, very little is known about the management of sexual dysfunction and current health care services do
not adequately meet sexual health needs of survivors. This project will examine the potential role of exercise in the
management of sexual dysfunction and evaluate a potential best-practice management approach by integrating
pharmacological, physiological and psychological treatment modalities to address the complex and multifaceted
aetiology of sexual dysfunction following cancer.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12613001179729.
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Increasing prostate cancer incidence (~56% increase since
1991) and survival rates (5-year survival rate increased
from ~58% to ~92% since 1987) coupled with an aging
population have led to a large and rapidly growing popula-
tion with unique health care requirements [1]. Sexual dys-
function is one of the most common, distressing and
persistent adverse effects of prostate cancer treatments
[2-11] which has a profound impact on quality of life both
for the patient and his partner [2-4,10,12-14]. The level of
concern associated with sexual dysfunction is reflected
by the willingness of men to sacrifice survival for sexual
potency (i.e. 68% of men are willing to sacrifice a ~10%
greater advantage in 5-year survival to maintain sexual
function) [15]. Up to 90% of men will experience sexual
dysfunction following primary therapy for prostate cancer
with treatments frequently leading to erectile dysfunction,
loss of libido, penile shortening and altered orgasmic ex-
perience [2-11]. Current health care services are inad-
equate to address the demand for management of sexual
dysfunction [3], with 47% of prostate cancer survivors
reporting unmet sexual health care needs [16]. Manage-
ment strategies predominately involve pharmacological
interventions to address the direct physiological effects
of prostate cancer treatment on erectile function [17,18].
However, the aetiology of sexual dysfunction is multifa-
ceted and there are considerable physiological and psycho-
logical side effects of prostate cancer treatments which
contribute to sexual dysfunction that are not counteracted
by pharmacological intervention [3,4,10]. Exercise has
established efficacy for improving many of these factors in
prostate cancer patients including changes in body com-
position (especially to counteract body feminisation with
androgen deprivation therapy [ADT]), fatigue, physical
function, risk of co-morbid conditions, inflammatory state,
depression, anxiety and quality of life [19-25]. Emerging
data indicates that exercise also fosters improved feelings
of masculinity and has a positive impact on libido in men
with prostate cancer [26,27], a concern that is highly
prevalent and difficult to treat [3,12]. Furthermore,
psychological therapies have established efficacy for
improving treatment induced psychological changes
associated with prostate cancer including depression
and anxiety as well as enhanced quality of life [28-31]
with emerging evidence for improving sexual health in
prostate cancer patients [32,33]. Therefore, a multidis-
ciplinary management strategy incorporating pharma-
cological (usual medical care), physiological (exercise
program) and psychological (brief psychosexual self-
management) interventions may represent a best-practice
model for addressing sexual dysfunction secondary to
prostate cancer treatment [27]. The relatively low uptake,
compliance and satisfaction with current treatment op-
tions [34-36] coupled with the low help-seeking andhealth service utilisation behavior of men [37-39] pro-
vides additional rationale for the novel management ap-
proach proposed. Hence, the aims of this study are to:
1. Examine the efficacy of exercise as a therapy to aid
in the management of sexual dysfunction in men
with prostate cancer.
2. Determine if combining exercise and brief
psychosexual self-management results in more
pronounced improvements in the sexual health of
men with prostate cancer.
3. Assess if any benefit of exercise and brief
psychosexual self-management on sexual dysfunction
in men with prostate cancer is sustained long term.
We will evaluate three main hypotheses: 1) Compared
with usual medical care, exercise will improve sexual
health in men with prostate cancer who are concerned
by sexual dysfunction. We theorise that exercise will im-
prove masculine self-esteem, quality of life, psychological
distress, fatigue, body composition, body image and
physical function, culminating in increased sexual health;
2) When exercise and brief psychosexual self-management
are combined, improvements in sexual health will exceed
those observed in usual medical care and exercise ther-
apy alone. We theorise that brief psychosexual self-
management will further enhance improvements in sexual
health through increasing men’s ability to better self-
manage their well-being and sexual dysfunction (i.e.
enhanced uptake of pharmacologic management of erect-
ile dysfunction); and 3) Improvements in sexual health will
be sustained 1 year after completion of the exercise and
combined exercise and psychosexual interventions. We
hypothesise that the theoretically based interventions will
prompt behavioural change that leads to sustained im-
provements in sexual health.
Despite being a critical survivorship care issue, there is
a clear gap in current knowledge of the optimal treatment
of sexual dysfunction in men with prostate cancer. The
current study will generate information to address this
gap. There is a strong theoretical rationale [27] and emer-
ging evidence [26] that exercise is an innovative therapy to
counteract sexual dysfunction in men with prostate can-
cer. However, there is a distinct lack of research investigat-
ing the efficacy of exercise on sexual health following
cancer treatment. Furthermore, despite the multidimen-
sional aetiology of sexual dysfunction, there is a paucity of
research investigating the efficacy of integrated treatment
models. This study will address these limitations. Findings
will expand current clinical guidelines for the management
of sexual dysfunction in men with prostate cancer and,
importantly, facilitate the development of targeted sup-
portive care services for survivors concerned by their
sexual health. Evidence gained may lead to a paradigm
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tate cancer survivors.
Methods/Design
A single-blinded (investigators blinded to group allocation),
three arm, multi-site randomised controlled trial (RCT)
design will be used to examine the efficacy of exercise
and psychosexual therapies on sexual health in men
with prostate cancer. An ‘Exercise’ group will complete
the exercise intervention, an ‘Exercise + Psychosexual’
group will complete the same exercise intervention as
well as a brief psychosexual self-management intervention
and a ‘Usual Care’ group will maintain usual medical care
for a period of 6 months. The Usual Care group will be of-
fered participation in the interventions at the completion
of the 6-month period (half to receive the Exercise inter-
vention and half the Exercise + Psychosexual intervention).
The RCT will be followed by a prospective cohort study
examining the long-term impact of exercise versus exer-
cise and brief psychosexual self-management on sexual
dysfunction in prostate cancer patients 1 year after the
interventions (Figure 1). The study will be guided by the
CONSORT statement [40].
Participants
Two hundred and forty men (80 subjects per arm)
treated for prostate cancer will be recruited by invitation
from their attending specialist (oncologist/urologist). Par-
ticipants will be recruited in Perth, Western Australia;
Brisbane, Queensland; Central and North Coasts of New
South Wales. Inclusion criteria are: 1) concern about
sexual health as assessed by an International Index of
Erectile Functioning (IIEF) overall satisfaction score < 8
(i.e. moderately-very dissatisfied) [41] and/or Expanded
Prostate Cancer Index Composite (EPIC) sexual bother
score > 8 (i.e. small-big problem) [42]; 2) prior/current
treatment for prostate cancer including prostatectomy,
radiotherapy or ADT; and 3) physician consent. Exclusion
criteria are: 1) non-nerve sparing prostatectomy; 2) > 6
months since prostatectomy or completion of radiother-
apy or ADT; 3) incontinence defined as requiring the useMonths                      0                             6    
EXERCISE GROUP Intervention
EXERCISE + PSYCHO-
SEXUAL GROUP
Intervention
USUAL CARE GROUP Usual care
Figure 1 Summary of the study design. Self-report measures also assess
the Exercise + Psychosexual groups; 18 months for the usual care group).of > 1 pad in a 24-hour period; 4) already performing regu-
lar exercise defined as undertaking structured aerobic or
resistance training two or more times per week within the
past 3 months; 5) acute illness or any musculoskeletal,
cardiovascular or neurological disorder that could inhibit
exercise or put participants at risk from exercising; and
6) unable to read and speak English. Eligible subjects will
undertake a series of familiarisation sessions and baseline
measurements prior to randomisation (Figure 2). The
protocol has been approved (ID: 10643 CORMIE) for all
participating centres by the Edith Cowan University
Human Research Ethics Committee and all participants
will provide written informed consent.Randomisation
Subjects will be randomly allocated in a ratio of 1:1:1 to
the three study arms, subject to maintaining approximate
balance regarding stratification for: 1) age (<60 years≥);
2) current sexual activity level (no/minor-moderate) as
assessed by the European Organisation for Research
and Treatment of Cancer (EORTC) prostate cancer spe-
cific questionnaire (QLQ-PR25) sexual activity score [43];
3) previous prostatectomy (yes/no); 4) previous radiother-
apy (yes/no); and 5) previous/current ADT (yes/no). A re-
search methods consultant with no patient contact will be
responsible for randomisation which will be performed
in Statistical Analysis System using the Pocock-Simon
minimisation algorithm.
The inclusion and exclusion criteria and stratification
procedures have been designed to control for the major
factors that may influence either baseline values and/or
the potential for change in sexual health throughout the
intervention (e.g. treatment type, time since treatment,
level of sexual health both pre-treatment and at baseline,
age, potential for recovery of function, incontinence).
Furthermore, in addition to clinically relevant covariates,
the main factors that could potentially confound the re-
sults will be assessed and adjusted for (e.g. utilisation of
sexual aids [pre-treatment, post-treatment and throughout
the study period], relationship status and satisfaction, any                      12                          18          24  
1 year Follow-up
1 year Follow-up
1 year Follow-upIntervention
ed at 6 months follow-up (i.e. at 12 months for both the Exercise and
Referral by oncologists/urologists in Western Australia, Queensland and New South Wales
Screening, familiarisation session and baseline testing
Patients stratified and randomised (n = 240)
Exercise                          
(n = 80)
Exercise + Psychosexual 
(n = 80)
Usual Care                       
(n = 80)
Receive allocated 
intervention for 6 months
Receive allocated 
intervention for 6 months
Maintain usual care for      
6 months
Post-intervention testing Post-usual care testing
Receive allocated 
intervention for 6 months
6 month follow-up testing (questionnaires only) Post-intervention testing
1 year follow-up testing
6 month follow-up testing 
(questionnaires only)
1 year follow-up testing
Figure 2 CONSORT diagram depicting the flow of participants throughout the trial.
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effects and co-morbidities influencing sexual health).
Measurements
All measurements for primary and secondary endpoints
will take place at baseline, post-intervention and 1 year
follow-up. The Usual Care group will undergo an add-
itional assessment point at the end of their delayed inter-
vention. All groups will complete an additional assessment
at 6 months follow-up involving the self-report question-
naires only. All assessments tools and procedures have
established validity and reliability and are used widely in
clinical research.
Primary study endpoints
Sexual health
The IIEF will be utilised to assess sexual health across a
variety of domains including erectile function, orgasmic
function, sexual desire, intercourse satisfaction and overallsatisfaction [41]. The Sexual Function scale of the EPIC is
a prostate cancer specific tool which will be utilised to as-
sess sexual function and satisfaction [42]. Sexual activity
level will be assessed using the sexual domain of the
QLQ-PR25 [43].
Secondary study endpoints
Secondary endpoints include key factors associated with
sexual health in men with prostate cancer.
Sexual self-confidence
The Short Form Psychological and Interpersonal Relation-
ship Scale will be used to assess sexual self-confidence
[44]. The Sexual Self-Efficacy Scale For Erectile Disorder
will be applied to assess sexual self-efficacy [45].
Masculine self-esteem
The Masculine Self-Esteem Scale is designed specifically
for use in men with prostate cancer and will be utilised
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The Personal Attributes Questionnaire will evaluate
masculinity [47].
Utilisation of sexual aids
A previously developed scale will be applied to assess
whether participants have sought medical assistance for
sexual dysfunction at any point before, during or after
prostate cancer treatment [34,48]. All treatments will be
documented and impact of these treatments rated.
Relationship satisfaction
The Dyadic Adjustment Scale will assess relationship
satisfaction between participants and their partners [49].
Sexual supportive care needs
The level of need for help with sexual dysfunction will
be assessed by the sexuality domain of the Supportive
Care Needs Survey [50].
Quality of life
Health-related quality of life will be assessed using the
Medical Outcomes Short Form 36 [51]. Quality of life will
also be assessed using a prostate cancer specific tool, the
EORTC QLQ-C30 and QLQ-PR25 questionnaires [52].
Urinary, bowel & hormonal issues
Adverse side effects specific to prostate cancer treatments
will be assessed using the urinary function, bowel habits
and hormonal function scales of the EPIC [42].
Psychological distress
The Brief Symptom Inventory-18 will be utilised to assess
psychological distress across the following domains: anxiety,
depression, somatisation and global distress severity [53].
Antidepressant use will also be recorded.
Fatigue
Cancer related fatigue will be assessed using the Func-
tional Assessment of Chronic Illness Therapy-Fatigue
questionnaire [54].
Body composition
Regional and whole body lean mass and fat mass will be
derived from whole body dual-energy X-ray absorptiometry
scans. Trunk adiposity, visceral fat and adipose indices will
be assessed using standard procedures [55].
Body image
The Body Image Scale is a cancer-specific scale that
will be used to assess participants’ perceptions of their
appearance [56].Physical function & physical activity levels
A series of standard tests will be used to assess physical
function: 1) 400-m walk (aerobic capacity), 2) one repeti-
tion maximum in the leg press and chest press (muscular
strength), 3) repeated chair rise (muscular power), 4) usual
and fast pace 6-m walk (ambulation), and 5) backwards
tandem 6-m walk (balance) [20,22,57]. Physical activity
levels will be assessed objectively over a 7-day period using
a validated, reliable tri-axial accelerometer activity monitor
(ActiGraph GT3X+) [58]. Self-reported physical activity
will also be assessed by the leisure score index from the
Godin Leisure-Time Exercise Questionnaire [59].
Blood biomarkers
Blood samples will be collected and analysed commercially
by accredited Australian National Association of Testing
Authorities laboratories for testosterone, high sensitivity
C-reactive protein (cardiovascular disease risk; also related
to severity of penile vascular disease) and prostate specific
antigen.
Exercise intervention
The exercise intervention involves a combination of aer-
obic and resistance exercise performed during 3 sessions
per week for 6 months. The program will be supervised by
accredited exercise physiologists in various exercise clinics
in Western Australia, Queensland and New South Wales.
The exercise sessions will be conducted in small groups of
up to 10–12 participants exercising in pairs or under dir-
ect supervision to ensure correct technique and minimise
the risk for injury. The exercise program is designed to
provide optimal stimulus to the cardiorespiratory and
neuromuscular systems while maximising safety, com-
pliance and retention. Specifically, the aerobic exercise
component will include 20 to 30 minutes of moderate
to vigorous intensity cardiovascular exercise (~60-85%
of estimated maximum heart rate) using a variety of
modes such as walking or jogging on a treadmill, cycling
or rowing on a stationary ergometer or exercising on an
elliptical or cross trainer machine. Participants will be
encouraged to undertake additional home-based aerobic
exercise with the goal of achieving a total of at least 150
minutes of moderate intensity aerobic exercise each week.
The resistance exercise component will involve 6–8 exer-
cises that target the major upper and lower body muscle
groups. Intensity will be manipulated from 6–12 repetition
maximum (RM; i.e. the maximal weight that can be lifted
6 to 12 times which is equivalent to ~60-85% of 1RM)
using 1–4 sets per exercise. To ensure the progressive na-
ture of the training program, participants will be encour-
aged to work past the specific RM prescribed. The
resistance will be increased by a 5-10% increment for the
next set or training session if the subject is able to perform
more repetitions than the RM specified during a set. Each
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prised of low-level aerobic activities as well as stretching
and conclude with a 5-minute cool-down period of
stretching activities. Exercise prescription will be pro-
gressive and modified according to individual response.
In order to reduce the possibility of boredom and over-
reaching, the exercise program will be periodised by
cycling emphasis on intensity and volume. The exercise
intervention has been designed in accordance with inter-
national guidelines [60,61]. Furthermore, we have used
this exercise prescription effectively in previous trials
involving men with prostate cancer and have reported
significant improvements in libido, quality of life, lean
muscle mass, fatigue, aerobic capacity, muscular strength,
physical function and C-reactive protein [20,22,23,26].
Exercise and psychosexual intervention
Participants receiving the combined exercise and psy-
chosexual support and self-management will complete
the exercise intervention described above as well as a brief
psychosexual self-management component that addresses
psychological and sexual well-being. A low intensity psy-
chological care approach will be utilised in order to maxi-
mise uptake and accessibility (i.e. facilitates translation)
[62]. Specifically, at baseline, participants will receive a
face to face brief psychosexual self-management session
with their exercise physiologist that addresses: stress man-
agement; problem solving coping for treatment challenges;
and goal setting for sexual rehabilitation. These sessions
will be audiotaped with 15% reviewed to ensure adher-
ence to the intervention protocol. The psychosexual self-
management intervention will apply cognitive behavioural
strategies; will utilise an adult learning approach in which
men self-select goals to focus on; and will encourage self-
management [63]. To support self-management men will
receive a psychosexual kit that includes a published self-
help book for men with prostate cancer and their partners
[64]; study specific tip sheets about treatments for erectile
dysfunction and goal setting for sexual rehabilitation; a
progress journal-diary; and audio resources for stress
management. The intervention delivered by the exercise
physiologist will be manualised and based on existing ma-
terials already developed and trialled by the team [31,48].
The exercise physiologists will receive extensive training
in how to deliver the intervention and continued supervi-
sion. Treatment fidelity will be managed consistent with
National Institute of Health guidelines [65]. This prag-
matic approach has been adopted based on the fact that
men are low help-seekers and incorporating strategies that
are linked to masculine ideals (i.e. exercising linked to
physical strength, self-management as self-reliance, peer
support offered through exercising in a group or ‘team’ of
men rather than a traditional support group setting) may
be more accepted by men and effective [37-39].Statistical analysis
Data from our previous 3-month study in prostate cancer
patients indicates that the standard deviation for change
in our primary outcome of sexual health equates to ~22
points on the QLQ-PR25 sexual activity domain [26]. We
observed the mean change after the intervention to differ
between exercise and usual care groups by ~11 points
[26]. There is no available evidence comparing changes in
sexual health between exercise and psychosexual interven-
tions. However, data from previous psychosexual interven-
tions in prostate cancer patients indicates changes of a
moderate standardised effect (d = 0.5) in sexual health
following the psycho-educational interventions [32,33].
We have based sample size calculations on the assump-
tion that there will be an additive effect of exercise and
psychosexual therapies. A priori, 64 participants per group
will be required to achieve 80% power at an alpha level of
0.05 (two tailed), and to demonstrate a difference between
the three groups in sexual health at the end of the inter-
vention. Previous experience in exercise and psychosexual
therapy trials indicates an attrition rate of up to 20%
over the intervention period. Therefore, to adequately
ensure that we have sufficient participant numbers at
the end of the intervention, 240 participants will be ran-
domised to the study arms. A sample size of 240 will
also provide us with sufficient power to detect a moder-
ate standardised effect (d = 0.5) in our secondary out-
comes. Based on previous experience we anticipate a
further attrition rate of up to 20% over the follow-up
period. Therefore, the sample size will provide 87% stat-
istical power to detect differences between the Exercise
group and the Exercise + Psychosexual group at follow-
up (d = 0.5; n = 77 per group as the usual care group will
be split between the two interventions for the prospect-
ive cohort study component of this project).
Data will be analysed using an intention-to-treat ap-
proach with maximum likelihood imputation of missing
values. Analyses will include standard descriptive statistics,
Student’s t-tests, chi-square, correlation and regression,
and two way (group × time) repeated measures ANOVA
(or ANCOVA as appropriate) to examine differences be-
tween groups over time. Clinically relevant covariates will
be included in analyses. All tests will be two-tailed and
an alpha level of 0.05 will be applied as the criterion for
statistical significance.
Discussion
Sexual dysfunction is one of the most prevalent, distres-
sing and lasting consequence of prostate cancer treat-
ment [2-11]. Despite this, very little is known about the
management of sexual dysfunction which is reflected by
the fact that current health care services do not ad-
equately meet the sexual health needs of prostate cancer
survivors [16]. Consequently, a significant proportion of
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ity of life and struggle to come to terms with redefining
their identity as a man [2-4,10,12-14,66,67]. Clearly, the
management of sexual dysfunction is a critical survivor-
ship care issue. This project will directly improve cancer
outcomes by enhancing survivorship care through the
development of effective, evidence-based supportive care
services. This project will be the first comprehensive
examination of the potential role of exercise in the man-
agement of sexual dysfunction in prostate cancer survivors.
Innovation is further exemplified by proposing and evalu-
ating a potential best-practice management approach, inte-
grating pharmacological (usual medical care), physiological
(exercise program) and psychological (brief psychosexual
self-management) treatment modalities to address the
complex and multifaceted aetiology of sexual dysfunc-
tion following cancer. Furthermore, the comprehensive
evaluation of factors associated with sexual health will
allow for a detailed analysis of the mechanisms driving
change in sexual dysfunction following exercise and
psychosexual therapies. We expect dissemination of the
knowledge gained from this study to advance cancer
care by improving sexual health, masculine self-esteem,
quality of life, psychological distress, fatigue, body com-
position, physical function and physical activity levels as
well as reducing risk factors for co-morbid conditions.
Knowledge gained will help expand clinical guidelines
for the effective management of sexual dysfunction sec-
ondary to prostate cancer and may lead to a paradigm
shift in current practice. The ultimate outcome will be
improved care for prostate cancer survivors through en-
hanced supportive care practice and policy.
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